ArticleJournal for immunotherapy of cancer2023

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.

Tian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.